Accordingly, they suggested that SB202190 could positively affect CRC organoid cultures without KRAS-activating mutations, relying on canonical EGFR signaling, while no explanation was hypothesized for SB202190’s inhibitory effect. The gene discussed is EGFR; the disease is colorectal carcinoma.